AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9400
-0.1100 (-5.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 2.0500
Open 2.0300
Bid 1.9300 x 1100
Ask 1.9900 x 900
Day's Range 1.9000 - 2.2000
52 Week Range 1.5600 - 9.2000
Volume 1,087,664
Avg. Volume 741,303
Market Cap 36.618M
Beta (3Y Monthly) 2.01
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Trade prices are not sourced from all markets
  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...

  • Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today
    InvestorPlace

    Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

    Some recent biopharma news concerning Akari Therapeutics has AKTX stock flying high on Wednesday.Source: Shutterstock The biopharma news has to do with Akari Therapeutics (NASDAQ:AKTX) getting Fast Track designation from the U.S. Food & Drug Administration (FDA) for one of its treatments. This allows the company to speed up testing of the drug. The designation is typically given to medicine with potential to treat illnesses that don't already have wide coverage.The Fast Track designation from the FDA is for Akari Therapeutics' nomacopan. This is the company's drug for treating HSCT-TMA. HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children that suffer from it. There currently isn't an approved treatment for this illness.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe positive biopharma news for AKTX stock comes after the successful treating of two patients in the U.S. with nomacopan. With these results and the FDA's approval, the company is now planning to launch a clinical trial of the treatment in the fourth quarter of 2019. * 15 Growth Stocks to Buy for the Long Haul "We see HSCT-TMA as a gateway into a range of other poorly treated orphan TMAs in both pediatric and adult patients, and are optimistic about the potential for nomacopan to offer an improved standard of care for these orphan conditions with high mortality rates," Clive Richardson, interim CEO of Akari Therapeutics, said in a statement.AKTX stock was up 32% as of Wednesday morning and is up 7% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch

    Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

    Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S. Food and Drug Administration. Trading volume swelled to 1.7 million shares, compared with the full-day average of about 96,000 shares. A Fast Track designation helps facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening conditions that address unmet medical needs. ""Fast Track designation provides our HSCT-TMA clinical program a pathway for an expedited approval for nomacopan, and we plan to commence a pivotal trial in the fourth quarter of 2019," said Chief Executive Clive Richardson. The stock has tumbled 42% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 2.9% and the S&P 500 has tacked on 3.2%.

  • Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility

    Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share...

  • Alexion's Ultomiris Receives EU Approval for PNH in Adults
    Zacks

    Alexion's Ultomiris Receives EU Approval for PNH in Adults

    Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

  • Alexion Receives FDA Approval for Label Expansion of Soliris
    Zacks

    Alexion Receives FDA Approval for Label Expansion of Soliris

    Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
    Zacks

    Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

    Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

  • Benzinga

    Akari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation

    Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The secondary objective of efficacy was assessed using a standard composite scoring system. Atopic keratoconjunctivitis is a serious corneal and eye surface disease which ultimately leads to visual impairment.

  • Benzinga

    The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) BIONDVAX PHARMA/S ADR (NASDAQ: BVXV ) Eidos Therapeutics ...

  • Benzinga

    Microcap Biotech Akari Rallies On Coversin Trial Results

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for ...

  • What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St.

    What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?

    Every investor in Akari Therapeutics, Plc (NASDAQ:AKTX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...

  • Benzinga

    The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 13) Abbott Laboratories (NYSE: ABT ) Akari Therapeutics ...

  • Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
    Zacks

    Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

    Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

  • Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
    Zacks

    Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

    Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

  • What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value
    Simply Wall St.

    What You Must Know About Akari Therapeutics, Plc’s (NASDAQ:AKTX) Beta Value

    If you own shares in Akari Therapeutics, Plc (NASDAQ:AKTX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...